^
Association details:
Biomarker:No biomarker
Cancer:Colon Cancer
Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
01/15/2018
Excerpt:
Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.
Secondary therapy:
Chemotherapy